Search for new potential biomarkers of non-alcoholic fatty liver disease progression in morbid obese patients

8^th International Conference and Exhibition on Metabolomics & Systems Biology

May 08-10, 2017 Singapore

Xiangping LIN1, Mohamed TRIBA, Nadia BOUCHEMAL, Carina Prip-Buus, Philippe SAVARIN

University of Paris 13, France

Scientific Tracks Abstracts: Metabolomics

Abstract :

The aim of this study was to uncover new potential biomarkers of Non-Alcoholic Fatty Liver Disease (NAFLD) progression in morbid obese patients (BMI�36kg/m2) referred for bariatric surgery. Liver biopsy and plasma of Non-NAFLD obese, histology-confirmed steatoses obese and histology-confirmed advanced grade of NAFLD: Non-alcoholic steatohepatitis (NASH) obese patients were obtained during bariatric surgery. After randomized, eligible liver sample was examined by HR-MAS 1H-NMR spectroscopy, eligible plasma of Non-NAFLD obese (n=18), steatoses obese (n=32) and NASH obese (n=21) patients were analyzed by a 500M Hz 1H-NMR spectroscopy. So far, Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) shows clear separation between Non-NAFLD obese and NASH obese patients, OPLS-DA and PLS-DA models were evaluated by internal 7-fold cross validation with Cross Validation Area Under Receiver Operating Characteristic (CV-AUROC) > 0.90 for Liver biopsy OPLS-DA model and CV-AUROC > 0.93 for plasma PLS-DA model. Plasma metabolites such as VLDL/LDL, lipid -CH2CH2CO, lipid -CH2CH=CH and lipid -CH2CO were significantly higher in NASH obese than in Non-NAFLD obese patients, plasma metabolomic profile appears to correlate with HR-MAS 1H-NMR liver biopsy metabolomic profile. Because of NMR resolution limit, those plasma samples will also analysis by a High-resolution mass spectrometry to get detail information on metabolites such as VLDL/LDLs, triglycerides, nonesterified fatty acids, phosphatidylcholines and ceramides. Furthermore, combing biochemical, genomic and transcriptomic data our study may shed light on mechanisms of mitochondrial dysfunction, hepatic lipid metabolism alterations during NAFLD progression.

Biography :

Xiangping LIN has completed his master's thesis “Urinary metabolomic profiling in the French Cohort SU.VI.MAX2 subjects to identify new biomarkers of apple consumption” at the French National Institute for Agricultural Research (INRA). He is doing now a PhD at CSPBAT Laboratory, University of Paris 13, and working on the “Obelix” project, this project aim to search new potential biomarkers of Non-Alcoholic Fatty Liver Disease progression in morbid obese patients referred for bariatric surgery by NMR, MS based metabolomics combined with biochemical, genomics, transcriptomics and statistical approaches.

Email: xiangping.lin@outlook.com